The Pharmacy Times® Chronic Obstructive Pulmonary Disease (COPD) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
A recent study found the prevalence of COPD was nearly 50% higher among patients with arthritis compared with those without arthritis, even after adjusting for sociodemographic characteristics, risk behaviors, frequent distress, and asthma status.
Interprofessional management of chronic obstructive pulmonary disease should include individualized approaches.
The combination treatment (Duaklir, Circassia) is designed to be administered twice-daily via AstraZeneca’s breath-actuated inhaler (Pressair).
The combination therapy was approved for twice-daily administration via the breath-actuated Pressair inhaler in patients with COPD.
Pharmacists have a great opportunity to educate patients about how to stay healthy and counsel those in need of symptom relief about their allergy treatment options.
Patients can breathe easier knowing that their local pharmacists are ideally positioned to help them manage their allegy, asthma and COPD conditions.
The FDA announced approval of Wixela Inhub on January 30, 2019.
The generic product (Wixela Inhub, Mylan) will be offered in 3 strengths at wholesale acquisition costs that are 70% less than the brand equivalent Advair Diskus, according to Mylan.
With new products coming to the pharmacy market, such as smart devices and digital medicines, the profession will need to develop quickly to keep up pace.
Mylan's drug is approved for 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg doses.
The generic drug (Wixela Inhub, Mylan) is indicated to treat patients with asthma and chronic obstructive pulmonary disease, including bronchitis and emphysema.
Teva has just unveiled the world's first integrated smart inhaler to the market.